{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:26:48Z","timestamp":1791260808108,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA234002"],"award-info":[{"award-number":["R37CA234002"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors are widely used in the treatment of estrogen receptor\u2013positive (ER\u207a) breast cancer; however, the metabolic adaptations induced by CDK4\/6 inhibition remain incompletely defined. In ER\u207a breast cancer, estrogen signaling plays a central role in coordinating cell cycle progression and metabolic programs that support tumor growth. Glycolytic flux is regulated at the level of phosphofructokinase-1 (PFK1) through the inducible enzyme 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase 3 (PFKFB3), which is transcriptionally regulated by estrogen receptor signaling and has been shown to promote glycolysis and proliferation in ER\u207a breast cancer cells. Yet, how CDK4\/6 inhibition intersects with estrogen-regulated glycolytic control to rewire glucose utilization in ER\u207a breast cancer has not been explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Glucose metabolism was assessed using extracellular flux analysis, untargeted metabolomics, and stable isotope tracing with uniformly labeled\n                      <jats:sup>13<\/jats:sup>\n                      C-glucose in ER+ breast cancer cell lines. In vivo metabolic tracing was performed following bolus administration of [U-\n                      <jats:sup>13<\/jats:sup>\n                      C]-glucose. The effects of pharmacologic PFKFB3 inhibition, alone and in combination with CDK4\/6 inhibitors, were evaluated in vitro and in patient-derived xenograft (PDX) models. Statistical analyses were performed using appropriate tests with correction for multiple comparisons where applicable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CDK4\/6 inhibition increased glycolytic flux, as evidenced by elevated basal and compensatory glycolysis, accumulation of early glycolytic intermediates, and increased\n                      <jats:sup>13<\/jats:sup>\n                      C labeling of fructose 1,6-bisphosphate. PFKFB3 deficiency significantly attenuated the CDK4\/6 inhibitor-induced increase in glycolytic flux. Despite increased glycolysis, stable isotope tracing revealed markedly reduced incorporation of glucose-derived carbon into nucleotide biosynthesis and lipid-associated metabolites, consistent with reduced anabolic demand during G1 cell cycle arrest. In vivo glucose tracing demonstrated a dissociation between increased glycolytic flux and downstream biosynthetic utilization. Pharmacologic inhibition of PFKFB3 imposed additional constraints on glucose utilization and significantly enhanced the antitumor efficacy of CDK4\/6 inhibition in PDX models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CDK4\/6 inhibition rewires glucose metabolism in ER+ breast cancer by increasing glycolytic flux while limiting downstream glucose utilization, resulting in heightened reliance on regulated glycolytic control to maintain metabolic homeostasis during cell cycle arrest. Disruption of this adaptive metabolic state through PFKFB3 inhibition enhances the antitumor effects of CDK4\/6 inhibition and supports the therapeutic potential of targeting glycolytic regulation in combination with CDK4\/6 inhibitor-directed therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02336-2","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T02:04:52Z","timestamp":1782353092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting PFKFB3 to enhance CDK4\/6 inhibitor response in ER+ breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Sucheta","family":"Telang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F","family":"Clem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariamna A Herrera","family":"Miret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xipeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chesney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoannis","family":"Imbert-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"2","key":"2336_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrc721","volume":"2","author":"S Ali","year":"2002","unstructured":"Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2(2):101\u201312.","journal-title":"Nat Rev Cancer"},{"key":"2336_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/or.2025.1564642","author":"Nayoung Kim","year":"2025","unstructured":"Kim N, Lukong KE. Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action. Oncol Reviews. 2025;Volume 19\u20132025. https:\/\/doi.org\/10.3389\/or.2025.1564642","journal-title":"Oncology Reviews"},{"key":"2336_CR3","doi-asserted-by":"crossref","unstructured":"Gnant M, Turner NC, Hernando C. Managing a Long and Winding Road: Estrogen Receptor\u2013Positive Breast Cancer. Am Soc Clin Oncol Educational Book. 2023(43):e390922. https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_390922.","DOI":"10.1200\/EDBK_390922"},{"issue":"28","key":"2336_CR4","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022;40(28):3246\u201356.","journal-title":"J Clin Oncol"},{"issue":"35","key":"2336_CR5","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(35):3959\u201377.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2336_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335.","journal-title":"Lancet Oncol"},{"issue":"18","key":"2336_CR7","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738\u201348.","journal-title":"N Engl J Med"},{"issue":"10","key":"2336_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942\u201350.","journal-title":"N Engl J Med"},{"issue":"1","key":"2336_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116\u201324.","journal-title":"JAMA Oncol"},{"issue":"10","key":"2336_CR10","doi-asserted-by":"publisher","first-page":"e2020312","DOI":"10.1001\/jamanetworkopen.2020.20312","volume":"3","author":"J Li","year":"2020","unstructured":"Li J, Huo X, Zhao F, Ren D, Ahmad R, Yuan X, et al. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor\u2013Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(10):e2020312\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2336_CR11","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2336_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-022-01510-6","volume":"24","author":"AC Watt","year":"2022","unstructured":"Watt AC, Goel S. Cellular mechanisms underlying response and resistance to CDK4\/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Res. 2022;24(1):17.","journal-title":"Breast Cancer Res"},{"key":"2336_CR13","doi-asserted-by":"publisher","first-page":"105859","DOI":"10.1016\/j.biocel.2020.105859","volume":"128","author":"B Zhang","year":"2020","unstructured":"Zhang B, Li D, Jin X, Zhang K. The CDK4\/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma. Int J Biochem Cell Biol. 2020;128:105859.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"2336_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-018-0741-3","volume":"37","author":"D Cretella","year":"2018","unstructured":"Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, et al. The anti-tumor efficacy of CDK4\/6 inhibition is enhanced by the combination with PI3K\/AKT\/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. J Exp Clin Cancer Res. 2018;37(1):72.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"2336_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15252\/msb.20167321","volume":"13","author":"M Tarrado-Castellarnau","year":"2017","unstructured":"Tarrado-Castellarnau M, de Atauri P, Tarrago-Celada J, Perarnau J, Yuneva M, Thomson TM, et al. De novo MYC addiction as an adaptive response of cancer cells to CDK4\/6 inhibition. Mol Syst Biol. 2017;13(10):940.","journal-title":"Mol Syst Biol"},{"key":"2336_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12935-020-01357-x","volume":"20","author":"LR Conroy","year":"2020","unstructured":"Conroy LR, Lorkiewicz P, He L, Yin X, Zhang X, Rai SN, et al. Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells. Cancer Cell Int. 2020;20:280.","journal-title":"Cancer Cell Int"},{"key":"2336_CR17","doi-asserted-by":"publisher","unstructured":"Santiappillai NT, Abuhammad S, Slater A, Kirby L, McArthur GA, Sheppard KE et al. CDK4\/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway. Cancers (Basel). 2021;13(3). https:\/\/doi.org\/10.3390\/cancers13030524.","DOI":"10.3390\/cancers13030524"},{"issue":"5","key":"2336_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.celrep.2015.12.094","volume":"14","author":"J Franco","year":"2016","unstructured":"Franco J, Balaji U, Freinkman E, Witkiewicz AK, Knudsen ES. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4\/6 Inhibition Elicits Unique Vulnerabilities. Cell Rep. 2016;14(5):979\u201390.","journal-title":"Cell Rep"},{"key":"2336_CR19","doi-asserted-by":"publisher","unstructured":"Lorito N, Bacci M, Smiriglia A, Mannelli M, Parri M, Comito G, et al. Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4\/6 Inhibitor Palbociclib(). Cells. 2020;9(3). https:\/\/doi.org\/10.3390\/cells9030668.","DOI":"10.3390\/cells9030668"},{"issue":"3","key":"2336_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.yexmp.2009.01.003","volume":"86","author":"A Yalcin","year":"2009","unstructured":"Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol. 2009;86(3):174\u20139.","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"2336_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10555-022-10027-5","volume":"41","author":"BC Jones","year":"2022","unstructured":"Jones BC, Pohlmann PR, Clarke R, Sengupta S. Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux. Cancer Metastasis Rev. 2022;41(2):447\u201358.","journal-title":"Cancer Metastasis Rev"},{"issue":"13","key":"2336_CR22","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1074\/jbc.M113.529990","volume":"289","author":"Y Imbert-Fernandez","year":"2014","unstructured":"Imbert-Fernandez Y, Clem BF, O\u2019Neal J, Kerr DA, Spaulding R, Lanceta L, et al. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). J Biol Chem. 2014;289(13):9440\u20138.","journal-title":"J Biol Chem"},{"issue":"1","key":"2336_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41523-024-00624-8","volume":"10","author":"R Foy","year":"2024","unstructured":"Foy R, Lew KX, Saurin AT. The search for CDK4\/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays. npj Breast Cancer. 2024;10(1):19.","journal-title":"npj Breast Cancer"},{"issue":"8","key":"2336_CR24","doi-asserted-by":"publisher","first-page":"100095","DOI":"10.1016\/j.mocell.2024.100095","volume":"47","author":"I Yoo","year":"2024","unstructured":"Yoo I, Ahn I, Lee J, Lee N. Extracellular flux assay (Seahorse assay): Diverse applications in metabolic research across biological disciplines. Mol Cells. 2024;47(8):100095.","journal-title":"Mol Cells"},{"issue":"3","key":"2336_CR25","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1042\/bj1920897","volume":"192","author":"E Van Schaftingen","year":"1980","unstructured":"Van Schaftingen E, Hue L, Hers HG. Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase. Biochem J. 1980;192(3):897\u2013901.","journal-title":"Biochem J"},{"issue":"1","key":"2336_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40170-024-00366-y","volume":"12","author":"N Lypova","year":"2024","unstructured":"Lypova N, Dougherty SM, Clem BF, Feng J, Yin X, Zhang X, et al. PFKFB3-dependent redox homeostasis and DNA repair support cell survival under EGFR-TKIs in non-small cell lung carcinoma. Cancer Metab. 2024;12(1):37.","journal-title":"Cancer Metab"},{"issue":"3","key":"2336_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. Genom Proteom Bioinform. 2022;20(3):587\u201396.","journal-title":"Genom Proteom Bioinform"},{"key":"2336_CR28","doi-asserted-by":"publisher","unstructured":"Conroy LR, Dougherty S, Kruer T, Metcalf S, Lorkiewicz P, He L, et al. Loss of Rb1 Enhances Glycolytic Metabolism in Kras-Driven Lung Tumors In Vivo. Cancers (Basel). 2020;12(1). https:\/\/doi.org\/10.3390\/cancers12010237.","DOI":"10.3390\/cancers12010237"},{"issue":"2","key":"2336_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141\u201362.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2336_CR30","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.","journal-title":"Sci Adv"},{"issue":"12","key":"2336_CR31","doi-asserted-by":"publisher","first-page":"105407","DOI":"10.1016\/j.jbc.2023.105407","volume":"299","author":"H Wu","year":"2023","unstructured":"Wu H, Kren BT, Lane AN, Cassel TA, Higashi RM, Fan TWM, et al. Cyclin D1 extensively reprograms metabolism to support biosynthetic pathways in hepatocytes. J Biol Chem. 2023;299(12):105407.","journal-title":"J Biol Chem"},{"issue":"7658","key":"2336_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nature22797","volume":"546","author":"H Wang","year":"2017","unstructured":"Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017;546(7658):426\u201330.","journal-title":"Nature"},{"key":"2336_CR33","doi-asserted-by":"publisher","first-page":"693104","DOI":"10.3389\/fonc.2021.693104","volume":"11","author":"MA George","year":"2021","unstructured":"George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S. Clinical and Pharmacologic Differences of CDK4\/6 Inhibitors in Breast Cancer. Front Oncol. 2021;11:693104.","journal-title":"Front Oncol"},{"issue":"9","key":"2336_CR34","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M. Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther. 2024;31(9):1283\u201391.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"2336_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41523-023-00520-7","volume":"9","author":"A Grinshpun","year":"2023","unstructured":"Grinshpun A, Tolaney SM, Burstein HJ, Jeselsohn R, Mayer EL. The dilemma of selecting a first line CDK4\/6 inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer. npj Breast Cancer. 2023;9(1):15.","journal-title":"npj Breast Cancer"},{"issue":"1","key":"2336_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10549-016-3968-8","volume":"160","author":"J O\u2019Neal","year":"2016","unstructured":"O\u2019Neal J, Clem A, Reynolds L, Dougherty S, Imbert-Fernandez Y, Telang S, et al. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2\u2009+\u2009breast cancer. Breast Cancer Res Treat. 2016;160(1):29\u201340.","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"2336_CR37","doi-asserted-by":"publisher","first-page":"24223","DOI":"10.1074\/jbc.M109.016816","volume":"284","author":"A Yalcin","year":"2009","unstructured":"Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL, et al. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. J Biol Chem. 2009;284(36):24223\u201332.","journal-title":"J Biol Chem"},{"issue":"7","key":"2336_CR38","doi-asserted-by":"publisher","first-page":"e1337","DOI":"10.1038\/cddis.2014.292","volume":"5","author":"A Yalcin","year":"2014","unstructured":"Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O\u2019Neal J, et al. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis. 2014;5(7):e1337\u2013e.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2336_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2049-3002-2-2","volume":"2","author":"AC Klarer","year":"2014","unstructured":"Klarer AC, O\u2019Neal J, Imbert-Fernandez Y, Clem A, Ellis SR, Clark J, et al. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer Metab. 2014;2(1):2.","journal-title":"Cancer Metab"},{"key":"2336_CR40","doi-asserted-by":"publisher","unstructured":"Lypova N, Dougherty SM, Lanceta L, Chesney J, Imbert-Fernandez Y. PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs. Cells. 2021;10(7). https:\/\/doi.org\/10.3390\/cells10071679.","DOI":"10.3390\/cells10071679"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02336-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02336-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02336-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:06:05Z","timestamp":1788908765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02336-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02336-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8412774\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the University Committee for Animal Welfare (UCAW) at the University of Louisville (protocol no. 22159).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"153"}}